Abstract：
OBJECTIVE: To analyze surgical outcomes and predictive factors for long-term overall and disease-specific survival in patients undergoing surgical resection of adrenal metastasis.
METHODS: A multicenter retrospective study included patients who underwent adrenalectomy for adrenal metastasis in two Spanish hospitals between 2005 and 2021. Clinical variables associated with surgical complications and survival during follow-up were analyzed.
RESULTS: Thirty-three patients were included. Adrenalectomy was performed laparoscopically in 27 patients and by an open approach in 6. The most common primary tumor site was the lung (n=15), followed by the kidney (n=7). Most patients had metachronous lesions (n=28). Six patients (18.2%) had intra- and/or postoperative complications; synchronous metastasis was a risk factor (odds ratio 12.5 [1.45-107.6]) for their development. Progression-free survival and disease-specific survival were 7.5months (range 1-64) and 22.5months (6-120), respectively. Survival rates at 1, 2, 3 and 5years were 94%, 65%, 48% and 29%, respectively. Survival was significantly lower in patients with lung cancer than with other cancers (hazard ratio 4.23 [1.42-12.59]).
CONCLUSIONS: Adrenalectomy for solitary adrenal metastases was associated with intra- or postoperative complications in 18% of cases. Synchronous metastasis was a risk factor for complications.
METHODS: A multicenter retrospective study included patients who underwent adrenalectomy for adrenal metastasis in two Spanish hospitals between 2005 and 2021. Clinical variables associated with surgical complications and survival during follow-up were analyzed.
RESULTS: Thirty-three patients were included. Adrenalectomy was performed laparoscopically in 27 patients and by an open approach in 6. The most common primary tumor site was the lung (n=15), followed by the kidney (n=7). Most patients had metachronous lesions (n=28). Six patients (18.2%) had intra- and/or postoperative complications; synchronous metastasis was a risk factor (odds ratio 12.5 [1.45-107.6]) for their development. Progression-free survival and disease-specific survival were 7.5months (range 1-64) and 22.5months (6-120), respectively. Survival rates at 1, 2, 3 and 5years were 94%, 65%, 48% and 29%, respectively. Survival was significantly lower in patients with lung cancer than with other cancers (hazard ratio 4.23 [1.42-12.59]).
CONCLUSIONS: Adrenalectomy for solitary adrenal metastases was associated with intra- or postoperative complications in 18% of cases. Synchronous metastasis was a risk factor for complications.
摘要：
目的：分析肾上腺转移手术切除患者的手术结果和长期总体生存和疾病特异性生存的预测因素。
方法：一项多中心回顾性研究包括2005年至2021年在西班牙两家医院因肾上腺转移而接受肾上腺切除术的患者。分析随访期间与手术并发症和生存率相关的临床变量。
结果：纳入33例患者。对27例患者进行了腹腔镜手术，对6例患者进行了开放手术。最常见的原发肿瘤部位是肺（n=15），其次是肾脏（n=7）。大多数患者有异时病变（n=28）。6例患者（18.2％）有手术中和/或术后并发症；同步转移是一个危险因素（比值比（OR）12.5[1.45-107.6]）。无进展生存期和疾病特异性生存期分别为7.5个月（范围1-64）和22.5个月（6-120），分别。1、2、3、5年生存率为94%,65%,48%和29%，分别。肺癌患者的生存率明显低于其他癌症患者（风险比4.23[1.42-12.59]）。
结论：在18％的病例中，孤立性肾上腺转移瘤的肾上腺切除术与术中或术后并发症相关。同步转移是并发症的危险因素。
方法：一项多中心回顾性研究包括2005年至2021年在西班牙两家医院因肾上腺转移而接受肾上腺切除术的患者。分析随访期间与手术并发症和生存率相关的临床变量。
结果：纳入33例患者。对27例患者进行了腹腔镜手术，对6例患者进行了开放手术。最常见的原发肿瘤部位是肺（n=15），其次是肾脏（n=7）。大多数患者有异时病变（n=28）。6例患者（18.2％）有手术中和/或术后并发症；同步转移是一个危险因素（比值比（OR）12.5[1.45-107.6]）。无进展生存期和疾病特异性生存期分别为7.5个月（范围1-64）和22.5个月（6-120），分别。1、2、3、5年生存率为94%,65%,48%和29%，分别。肺癌患者的生存率明显低于其他癌症患者（风险比4.23[1.42-12.59]）。
结论：在18％的病例中，孤立性肾上腺转移瘤的肾上腺切除术与术中或术后并发症相关。同步转移是并发症的危险因素。
